CAR T-cell therapy showed encouraging efficacy and good safety in newly diagnosed Ph-positive ALL,” the researchers wrote.

Researchers used FAERS data to understand and identify adverse drug reactions associated with capmatinib intake, newly identifying ototoxicity as a possible reaction.

The average number of industry-funded trials started per month was 135.8 before the IRA was passed and 83.6 after — a 38.4% decrease.

Investigators examined the effect of immunosuppression on poor outcomes among patients with cutaneous squamous cell carcinoma.

The ASCENT-03 trial is a phase 3 study assessing the efficacy and safety of sacituzumab govitecan compared with physician’s choice of treatment in patients with previously untreated, locally advanced, ...

Findings seen in women with moderate-to-severe vasomotor symptoms associated with endocrine therapy for HR-positive breast cancer.

Researchers studied the progression-free and overall survival rates of patients with advanced melanoma after cessation of immune checkpoint inhibitor therapy.

Normal catheter function was observed among 85.7%. No complete catheter occlusion was observed. Aspiration problems were observed in 9 cases, and both injection and aspiration problems in 1 case.

Psychological and informational needs are the most common unmet needs among adult survivors of thyroid cancer, according to findings from a systematic review published in JAMA Otolaryngology-Head & ...

Regarding the pediatric population, mold-active antifungal prophylaxis is recommended for pediatric patients at high risk of IFD, including a subgroup of children with ALL.

Data from the DeLLphi-304 trial “clearly support tarlatamab as a preferable therapy” for SCLC in the second-line setting, said Charles M. Rudin, MD, PhD.

The combination of toripalimab, nimotuzumab, and chemotherapy showed “promising antitumor activity with acceptable toxicity,” researchers wrote.